NIH

Taylor, formerly of the University of Louisville, is known for his discovery of and research on tumor-secreted exosomes.  

On average, researchers’ impact dropped by one-half to two-thirds over their careers.

An influential paper on amyloid protein and Alzheimer’s disease potentially fabricated data. Why did it take 16 years to flag?

Seventeen studies coauthored by Gregg Semenza have been retracted, corrected, or raised for concern, and 15 more are currently under investigation.

The National Institute of Allergy and Infectious Diseases was not aware that the work involved a chimeric strain of SARS-CoV-2, STAT reports.

As the new agency’s director, the DARPA veteran will spearhead a high-risk, high-reward approach to biomedical research.

Researchers who work with materials such as fetal tissue and human embryonic stem cells are facing new restrictions, the latest in a long line of regulations, that could impede important advances.

Projects funded by the National Institutes of Health increasingly employ subjective and promotional language in describing research, a study finds.

The 81-year-old director says that he will step back from his positions this December, but that he will continue working to advance science and public health.

A review by the US Office of Inspector General found that only about half of the scientists running clinical trials funded by the NIH in 2019 and 2020 appropriately recorded their findings in a federal database, as is legally required.

A lack of comprehension among some researchers about how to use ClinicalTrials.gov may be hindering public access to trial information and holding up drug study results, an investigation by The Scientist finds.

Makio Murayama, a Japanese-American biochemist who was turned away from the Manhattan Project due to his heritage, rose to prominence for his work uncovering the link between the structure of hemoglobin and the mechanisms of sickle cell disease.

A review of more than two decades of data finds racial disparities in the success rate of National Science Foundation grant proposals.

A new presidential memorandum requires the Department of Health and Human Services to coordinate a government-wide push to generate a research action plan for the condition.

After lobbying efforts from lawmakers and science advisors, the new, DARPA-like biomedical research agency will be a part of the National Institutes of Health, but its director will report directly to the secretary of Health and Human Services.

The retracted studies were coauthored by a scientist who worked on an Alzheimer’s therapy in development by Cassava Sciences, a company reportedly under investigation for providing falsified data to the FDA.

And does it even matter?

The University of Washington researcher leveraged data from the Human Genome Project to identify genes underlying various health conditions and advance precision medicine.

The glycoprotein researcher and longtime principal deputy director of the National Institutes of Health will take over from Francis Collins on December 20.